Amyloid beta (Aβ)
Amyloid beta (Aβ) is a short peptide, typically 36–43 amino acid long, generated in the human brain and peripheral tissues.
Amyloid beta (Aβ) is a short peptide, typically 36–43 amino acid long, generated in the human brain and peripheral tissues. It is produced by sequential proteolytic cleavage of the transmembrane amyloid precursor protein (APP): beta-secretase 1 (BACE1) cuts APP first, and the gamma-secretase complex then releases Aβ from the membrane. Cleavage site heterogeneity yields peptides of differing length, of which Aβ40 and the more aggregation-prone Aβ42 predominate. Aβ monomers are natively unstructured and readily self-assemble into oligomers, protofibrils, and β-sheet-rich fibrils, the latter forming the extracellular amyloid plaques that, together with tau (MAPT) neurofibrillary tangles, define the neuropathological diagnosis of Alzheimer's disease. Aβ is also deposited in the walls of cerebral vessels in cerebral amyloid angiopathy.
The peptide's biological significance rests on both its normal turnover and its pathological accumulation. Clearance across the blood–brain barrier and through perivascular and lymphatic drainage routes balances production, and imbalance in this equilibrium is the basis of the amyloid cascade hypothesis, in which Aβ accumulation precedes tau hyperphosphorylation — a process linked to kinases such as GSK-3β — neuroinflammation, and neuronal loss. Soluble Aβ oligomers, rather than mature plaques alone, are considered the more synaptotoxic species; proposed downstream mechanisms include NLRP3 inflammasome activation and release of proinflammatory cytokines such as Tnf-α, mitochondrial dysfunction with generation of reactive oxygen species and oxidative stress, caspase-3-mediated apoptosis, and interaction with redox-active metals including copper. Aβ is central to Alzheimer's disease diagnostics and therapeutics: cerebrospinal fluid Aβ42 and amyloid PET tracers stage pathology in preclinical and mild cognitive impairment stages alongside tau markers such as plasma p-tau217, while anti-Aβ monoclonal antibodies, including aducanumab and lecanemab, clear amyloid from the brain and carry a characteristic risk of amyloid-related imaging abnormalities (ARIA). BACE1 inhibitors, small molecules that block APP cleavage by inhibiting the β-secretase enzyme, and neuroprotective natural products such as Ginkgo biloba extract represent additional strategies aimed at reducing Aβ burden or blunting its toxicity.
Where the papers sit
28 papers from the last 6 months study Amyloid beta (Aβ) directly · updated from PubMed 15 Nov 2026
Study type 1 clinical trial · 5 observational · 8 human data · 14 preclinical
Themes 4 themes · 1 paradigm shift · 1 new direction
-
Amyloid Toxicity and Therapy
Amyloid-β work is moving beyond aggregation alone toward chelation, targeted delivery, and cellular protection. Albumin and liposomal nanoparticles are being tailored to limit hepatic sequestration while preserving brain exposure, and aducanumab provides a clinical immunotherapy comparator. Equol, ribavirin, and ellagic acid converge on stress or clearance pathways, including PEK-1-linked UPRer, lysosomes, and ISR. Metal ions, membrane disruption, synaptic loss, and ATN progression remain mechanistic and translational endpoints.
9 papers · 32.1%
-
Tau Biomarkers in Alzheimer Disease
Tau biomarkers are being used to define Alzheimer disease trajectories before dementia and to connect amyloid burden with cognition. Plasma p-Tau217 and p-Tau181 are repeatedly compared with CSF measures, imaging, cerebral blood flow, and white-matter injury. Longitudinal cohorts and combined tau profiles aim to distinguish preclinical stages and predict cognitive decline or treatment response. Cross-platform assay comparisons and validation pipelines show that standardization remains the main barrier to clinical deployment.
7 papers · 25%
-
Blood–Brain Barrier Amyloid Targeting
Blood–brain barrier transport is emerging as a central constraint on amyloid diagnosis and treatment. P-glycoprotein, endothelial accumulation, and butyrate-sensitive barrier handling are linked to cerebral exposure and neurodegeneration. ApoE3-targeted liposomes, antibody comparisons involving ACU193 and lecanemab, and small-molecule neuroprotectants seek more selective brain delivery. PET, fluorescence-lifetime detection, and NIR photosensitization extend the field toward combined amyloid imaging and intervention.
6 papers · 21.4%
-
Amyloid Biomarkers and Neuroprotection
Amyloid assessment is being tied to cognition, neuroinflammation, and cerebral amyloid angiopathy rather than treated as an isolated signal. Plasma metabolite and protein signatures, p-tau181, and head-to-head assay testing aim to improve amyloid positivity and risk classification across early disease. Experimental therapies pair amyloid or cholinesterase inhibition with anti-inflammatory and synaptic protection, including aurantio-obtusin and phytochemical carbamate hybrids. Personalised therapy and reuse of clinical data remain proposed extensions, while assay comparability and validation are unresolved.
6 papers · 21.4%
Amyloid-β reduction does not necessarily arrest tau pathology or its association with neurodegeneration
The postmortem study of aducanumab-treated patients with Alzheimer disease found robust reduction of brain Aβ and parallel reduction of neuritic phospho-tau, but no change in PHF-1+ or AT8+ neurofibrillary tangle density 42301522Jun; independently, the ADNI3 multimodal imaging study found that posterior tau was associated with reduced cerebral blood flow even after accounting for Aβ 42554925Aug. Together, these findings challenge a strictly linear account in which removing Aβ should halt downstream tau pathology and neurodegeneration: some established tau pathology and tau-related vascular dysfunction may persist or operate partly independently of Aβ burden.
Aggregated amyloid-β can function as a signaling ligand for APP that reinforces amyloidogenesis
The gallein-loaded albumin nanoparticle study in murine neuroblastoma cells, primary rat cortical neurons, and human iPSC-derived neurons treated with aggregated Aβ identifies APP as a receptor for aggregated Aβ species, with downstream Go/Gβγ signaling that promotes amyloidogenic APP processing, dendritic pathology, and synaptic loss 42563066Aug. This assigns Aβ a receptor-mediated, self-reinforcing signaling role rather than treating it only as an accumulated toxic aggregate, suggesting that blocking Aβ-triggered APP–Gβγ signaling could interrupt amyloidogenesis and neuronal injury even without directly removing existing Aβ deposits.
Papers
The 28 papers from the last 6 months that study Amyloid beta (Aβ) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Amyloid Toxicity and Therapy (9)
- Liposomal Formulation of Ellagic Acid Counteracts Amyloid-β Oligomer-Induced Cellular Stress: Influence of Neuronal Differentiation. ChemMedChem · 24 Oct 2026 PMID 42922079
- Beyond statistical thresholds: Mapping sequential ATN cascade transitions via brain structural topography in Alzheimer's disease. Science advances · 23 Sept 2026 PMID 42777020
- Size-tailored nanoparticle-antibody conjugates overcome hepatic sequestration in Alzheimer's disease treatment. Proceedings of the National Academy of Sciences of the United States of America · 8 Sept 2026 PMID 42709795
- Metal-Ion-Mediated Amyloid- β Aggregation in Alzheimer's Disease: A Mathematical Model of Chelation and Inhibitory Therapies. Bulletin of mathematical biology · 21 Aug 2026 PMID 42624961
- Gallein-Loaded Albumin Nanoparticles Prevent Amyloid-β-Induced Amyloidogenic APP Processing, Synaptic Loss, and Dendritic Pathology. Molecular neurobiology · 7 Aug 2026 PMID 42563066
- Ribavirin mitigates Alzheimer's disease model phenotypes by enhancing lysosomal function and suppressing ISR. Bioorganic chemistry · 30 Jun 2026 PMID 42379016
- Neuropathological study of the effects of aducanumab anti-Aβ immunotherapy on patients with Alzheimer's disease. Acta neuropathologica · 16 Jun 2026 PMID 42301522
- Bacteria-derived equol alleviates Aβ toxicity in C. elegans through PEK-1-associated UPRer activation. Biochemical and biophysical research communications · 8 Jun 2026 PMID 42259196
- Electrostatic control of membrane disruption and amorphous coaggregation by dynorphin A variants. Biochemical and biophysical research communications · 3 Jun 2026 PMID 42235331
Tau Biomarkers in Alzheimer Disease (7)
- Changes in five cerebrospinal fluid and three plasma Alzheimer's disease biomarkers across increasing brain amyloid-beta and tau pathology burden. Acta neuropathologica · 3 Sept 2026 PMID 42690439
- The Associations of cerebral blood flow and white matter hyperintensities with tau and amyloid-beta across the Alzheimer's disease spectrum. Brain imaging and behavior · 5 Aug 2026 PMID 42554925
- Standardized Extract of Ginkgo biloba L. Reverses Memory Impairment in Older Female Mice with Basal Forebrain Cholinergic Dysfunction. Neurochemical research · 13 Jul 2026 PMID 42443567
- The Cerebrospinal Fluid Proteome of Alzheimer's Disease Patients: Differentiation and Prediction of Responders and Non-Responders to Lymphatic-Venous Anastomosis. Analytical chemistry · 25 Jun 2026 PMID 42350157
- Clinico-biological trajectories stratified by combined tau biomarkers in preclinical Alzheimer's disease. Alzheimer's research & therapy · 24 Jun 2026 PMID 42337598
- Alzheimer's disease neuropathology plasma biomarkers and cognition in midlife: a community-based cohort study. Lancet (London, England) · 28 May 2026 PMID 42208562
- Model Validation Pipeline Against Longitudinal Alzheimer's Biomarker Data. Neuroinformatics · 23 May 2026 PMID 42176081
Blood–Brain Barrier Amyloid Targeting (6)
- Engineering ApoE3-Targeted NIR-Responsive Liposomes for Multimodal Inhibition of Amyloid-β Aggregation and Acetylcholinesterase Activity. ACS chemical neuroscience · 19 Aug 2026 PMID 42615643
- Novel Xanthene Derivatives for Neuroprotection in Alzheimer's Disease-Synthesis and Biological Assessment. ChemMedChem · 30 Jun 2026 PMID 42380051
- Bithiophene Scaffold for PET Imaging and Photosensitization as a Novel Theranostic Platform Targeting Amyloid-β Aggregates. ACS chemical neuroscience · 30 Jun 2026 PMID 42376965
- Fluorescence Lifetime and Smartphone-Enabled Detection of Amyloid-β for Diagnosis and Staging in Alzheimer's Disease. ACS chemical neuroscience · 18 Jun 2026 PMID 42314111
- Ex vivo comparison of ACU193 and lecanemab reveals binding differences in mouse brain. Alzheimer's & dementia : the journal of the Alzheimer's Association · 1 Jun 2026 PMID 42222928
- Butyrate Regulates the Blood-Brain Barrier Transport and Intraendothelial Accumulation of Alzheimer's Disease Amyloid-Beta Peptides. Molecular pharmaceutics · 21 May 2026 PMID 42166642
Amyloid Biomarkers and Neuroprotection (6)
- Circulating Metabolite Signatures Associated With Amyloid Positivity, Cognitive Performance and Plasma P-tau181 Levels in Cognitively Unimpaired Older Adults. Molecular neurobiology · 13 Sept 2026 PMID 42733048
- Head-to-head comparison of plasma biomarker assays across platforms for amyloid pathology in a multicenter cohort. Science bulletin · 23 Aug 2026 PMID 42633973
- Aurantio-Obtusin Attenuates Aβ-Induced Cognitive Impairment and Synaptic Dysfunction by Suppressing Neuroinflammation in Mice. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 6 Aug 2026 PMID 42560407
- Rationally designed phytochemical-derived carbamate hybrids unveiling potent inhibition of cholinesterase and amyloid-β peptides. Bioorganic chemistry · 11 Jul 2026 PMID 42435703
- Turning failure into success: how artificial intelligence can help personalize therapies and re-use patient data. Purinergic signalling · 29 May 2026 PMID 42213219
- A plasma protein signature for cerebral amyloid angiopathy. Acta neuropathologica · 20 May 2026 PMID 42162487
By study type
Clinical trials (1)
- Clinico-biological trajectories stratified by combined tau biomarkers in preclinical Alzheimer's disease. Alzheimer's research & therapy · 24 Jun 2026 PMID 42337598
Observational studies and case reports (5)
- Head-to-head comparison of plasma biomarker assays across platforms for amyloid pathology in a multicenter cohort. Science bulletin · 23 Aug 2026 PMID 42633973
- The Associations of cerebral blood flow and white matter hyperintensities with tau and amyloid-beta across the Alzheimer's disease spectrum. Brain imaging and behavior · 5 Aug 2026 PMID 42554925
- Alzheimer's disease neuropathology plasma biomarkers and cognition in midlife: a community-based cohort study. Lancet (London, England) · 28 May 2026 PMID 42208562
- Model Validation Pipeline Against Longitudinal Alzheimer's Biomarker Data. Neuroinformatics · 23 May 2026 PMID 42176081
- A plasma protein signature for cerebral amyloid angiopathy. Acta neuropathologica · 20 May 2026 PMID 42162487
Human data, design not indexed (8)
- Beyond statistical thresholds: Mapping sequential ATN cascade transitions via brain structural topography in Alzheimer's disease. Science advances · 23 Sept 2026 PMID 42777020
- Circulating Metabolite Signatures Associated With Amyloid Positivity, Cognitive Performance and Plasma P-tau181 Levels in Cognitively Unimpaired Older Adults. Molecular neurobiology · 13 Sept 2026 PMID 42733048
- Changes in five cerebrospinal fluid and three plasma Alzheimer's disease biomarkers across increasing brain amyloid-beta and tau pathology burden. Acta neuropathologica · 3 Sept 2026 PMID 42690439
- Metal-Ion-Mediated Amyloid- β Aggregation in Alzheimer's Disease: A Mathematical Model of Chelation and Inhibitory Therapies. Bulletin of mathematical biology · 21 Aug 2026 PMID 42624961
- The Cerebrospinal Fluid Proteome of Alzheimer's Disease Patients: Differentiation and Prediction of Responders and Non-Responders to Lymphatic-Venous Anastomosis. Analytical chemistry · 25 Jun 2026 PMID 42350157
- Neuropathological study of the effects of aducanumab anti-Aβ immunotherapy on patients with Alzheimer's disease. Acta neuropathologica · 16 Jun 2026 PMID 42301522
- Electrostatic control of membrane disruption and amorphous coaggregation by dynorphin A variants. Biochemical and biophysical research communications · 3 Jun 2026 PMID 42235331
- Turning failure into success: how artificial intelligence can help personalize therapies and re-use patient data. Purinergic signalling · 29 May 2026 PMID 42213219
Preclinical: animal, cell and lab studies (14)
- Liposomal Formulation of Ellagic Acid Counteracts Amyloid-β Oligomer-Induced Cellular Stress: Influence of Neuronal Differentiation. ChemMedChem · 24 Oct 2026 PMID 42922079
- Size-tailored nanoparticle-antibody conjugates overcome hepatic sequestration in Alzheimer's disease treatment. Proceedings of the National Academy of Sciences of the United States of America · 8 Sept 2026 PMID 42709795
- Engineering ApoE3-Targeted NIR-Responsive Liposomes for Multimodal Inhibition of Amyloid-β Aggregation and Acetylcholinesterase Activity. ACS chemical neuroscience · 19 Aug 2026 PMID 42615643
- Gallein-Loaded Albumin Nanoparticles Prevent Amyloid-β-Induced Amyloidogenic APP Processing, Synaptic Loss, and Dendritic Pathology. Molecular neurobiology · 7 Aug 2026 PMID 42563066
- Aurantio-Obtusin Attenuates Aβ-Induced Cognitive Impairment and Synaptic Dysfunction by Suppressing Neuroinflammation in Mice. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 6 Aug 2026 PMID 42560407
- Standardized Extract of Ginkgo biloba L. Reverses Memory Impairment in Older Female Mice with Basal Forebrain Cholinergic Dysfunction. Neurochemical research · 13 Jul 2026 PMID 42443567
- Rationally designed phytochemical-derived carbamate hybrids unveiling potent inhibition of cholinesterase and amyloid-β peptides. Bioorganic chemistry · 11 Jul 2026 PMID 42435703
- Novel Xanthene Derivatives for Neuroprotection in Alzheimer's Disease-Synthesis and Biological Assessment. ChemMedChem · 30 Jun 2026 PMID 42380051
- Ribavirin mitigates Alzheimer's disease model phenotypes by enhancing lysosomal function and suppressing ISR. Bioorganic chemistry · 30 Jun 2026 PMID 42379016
- Bithiophene Scaffold for PET Imaging and Photosensitization as a Novel Theranostic Platform Targeting Amyloid-β Aggregates. ACS chemical neuroscience · 30 Jun 2026 PMID 42376965
- Fluorescence Lifetime and Smartphone-Enabled Detection of Amyloid-β for Diagnosis and Staging in Alzheimer's Disease. ACS chemical neuroscience · 18 Jun 2026 PMID 42314111
- Bacteria-derived equol alleviates Aβ toxicity in C. elegans through PEK-1-associated UPRer activation. Biochemical and biophysical research communications · 8 Jun 2026 PMID 42259196
- Ex vivo comparison of ACU193 and lecanemab reveals binding differences in mouse brain. Alzheimer's & dementia : the journal of the Alzheimer's Association · 1 Jun 2026 PMID 42222928
- Butyrate Regulates the Blood-Brain Barrier Transport and Intraendothelial Accumulation of Alzheimer's Disease Amyloid-Beta Peptides. Molecular pharmaceutics · 21 May 2026 PMID 42166642
Written from 28 PubMed abstracts, each one listed by PMID above. Published: 2026-06-17. Last written: 2026-09-25 by GPT. Corrections: 2026-09-26 by GPT. Reviewed by a human editor on 2026-07-23. Drafted by language models from published abstracts; not medical advice.